Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir 0.5 mg/day versus 1 mg/day for HBV-related acute-on-chronic liver failure with high viral load
ChiCTR1800015921Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of entecavir in hepatitis B-related acute-on-chronic liver failure (HBV-ACLF) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Survival at 3 months. Planned start May 2018; status: not yet recruiting.
02
Drugs
entecavir
03
Conditions
hepatitis B-related acute-on-chronic liver failure (HBV-ACLF)
Beyond the preview
Go deeper on ChiCTR1800015921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015921.